MPM Bioimpact LLC Buys Shares of 257,788 Vera Therapeutics, Inc. (NASDAQ:VERA)

MPM Bioimpact LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 257,788 shares of the company's stock, valued at approximately $10,902,000. MPM Bioimpact LLC owned about 0.41% of Vera Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC raised its stake in Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Vera Therapeutics by 11.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock worth $185,107,000 after purchasing an additional 437,940 shares during the period. FMR LLC grew its stake in Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after purchasing an additional 267,842 shares during the period. Vanguard Group Inc. grew its stake in Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after purchasing an additional 369,387 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its stake in Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock worth $60,785,000 after purchasing an additional 340,488 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on VERA. HC Wainwright began coverage on Vera Therapeutics in a research note on Monday, May 5th. They issued a "buy" rating and a $75.00 price target on the stock. Wedbush dropped their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective on the stock. Finally, Guggenheim lifted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Vera Therapeutics has an average rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Stock Down 0.4%

VERA traded down $0.08 during trading on Friday, hitting $21.25. 955,320 shares of the company's stock traded hands, compared to its average volume of 780,251. The company's 50 day simple moving average is $23.49 and its two-hundred day simple moving average is $34.01. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.14 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the company posted ($0.56) EPS. Analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.